Madrid, January 8, 2025.- According to data from the Spanish Network of Cancer Registries (REDECAN) and the Spanish Society of Hematology and Hemotherapy (SEHH)[1], it is projected that hematological cancer will become the fifth most frequent tumour in Spain by 2025. In this context MD Anderson Cancer Center Madrid - Hospiten announces the incorporation of CAR-T therapy, a revolutionary advance in the treatment of complex hematological diseases.
CAR-T therapy, considered one of the most significant advances in hematological oncology, uses the patient's own T lymphocytes - which are then genetically modified in a laboratory to specifically target malignant cells. This procedure is recommended for patients with B-cell acute lymphoblastic leukemia, diffuse large cell lymphoma, follicular lymphoma and mantle cell lymphoma, primarily in cases where conventional treatments have failed.
In the words of Dr. Adolfo de la Fuente, Head of the Hematology and Hemotherapy Department at MD Anderson Madrid – Hospiten, "This advance represents a unique opportunity for patients with complex hematological diseases, offering them the possibility of treatment and potential cure in cases where previously there were no viable alternatives,"
A paradigm shift in the approach to hematological cancers
As our specialist explains, the process begins with the collection of T lymphocytes from the patient via apheresis, a technique that separates the components of the blood. These cells are manipulated in a bioreactor, using viral vectors to integrate a chimeric receptor (CAR) that allows the identification and elimination of tumour cells. Once modified, the cells are reinfused into the patient, where they start to act as a ‘living medicine’ capable of fighting the disease.
"CAR-T therapy represents a paradigm shift in the approach to hematological cancers, especially for patients who have no other therapeutic options," he adds.
Although this treatment represents a revolutionary advance, it is not without risks, as Dr. Adolfo de la Fuente indicates: "Adverse effects including neurological complications can become serious, so it is essential to have highly qualified teams on hand and ensure rigorous control at every stage of the process. This involves Hematology, Intensive Care and Neurology teams, all working in close coordination to prevent and manage any complications that may arise".
However, the benefits of CAR-T therapy still far outweigh these risks, especially in cases of patients with a limited prognosis after having exhausted other therapeutic options.
In this way, the incorporation of CAR-T therapy further reinforces the position of MD Anderson Cancer Center Madrid-Hospiten as a centre of reference in the fight against hematological cancer, reaffirming its commitment to innovation and excellence in health care. "This innovative therapeutic strategy offers a unique opportunity for those who previously had no alternatives", concludes the specialist.
References:
- Blood Cancer Figures in Spain